Sophia Primary Analysis: A Phase 3 (P3) Study of Margetuximab (M) plus Chemotherapy (C) Versus Trastuzumab (T) plus C in Patients (Pts) with Her2+Metastatic (Met) Breast Cancer (Mbc) After Prior Anti-Her2 Therapies (Tx).

AuthID
 P-00R-4AD
19
Author(s)
Im, SA
·
Wright, GLS
·
Escriva de Romani, S
·
DeLaurentiis, M
·
Cortes, J
·
Bahadur, SW
·
Haley, BB
·
Oyola, RH
·
Riseberg, DA
·
Musolino, A
·
Cardoso, F
·
Curigliano, G
·
Kaufman, PA
·
Pegram, MD
·
Edlich, S
·
Hong, S
·
Rock, EP
·
Gradishar, WJ
Document Type
Abstract
Year published
2019
Published
in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X
Volume: 37, Issue: 15
Conference
Annual Meeting of the American-Society-Of-Clinical-Oncology (Asco), Date: MAY 31-JUN 04, 2019, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol
Indexing
Wos®
Google Scholar®
Publication Identifiers
Wos: WOS:000487345803587
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Marked List
 Add to Marked List
Citations
Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

CORE Conference
No information about CORE Rank

During the preprocessing phase, only publications of type 'Proceedings Paper' or 'Proceedings' are automatically processed to identify their CORE Rank.

TIP: If your publication's CORE Rank is missing, you can contact with your institutional manager to have the correct ranking manually added to the record.

Journal Factors
Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

Info
At this moment we don't have any links to full text documens.

footer slogan

Useful Links

Get Help

© 2026 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service